Vaishali Pharma Limited
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti"malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-vir… Read more
Vaishali Pharma Limited (VAISHALI) - Total Liabilities
Latest total liabilities as of September 2025: ₹545.40 Million INR
Based on the latest financial reports, Vaishali Pharma Limited (VAISHALI) has total liabilities worth ₹545.40 Million INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vaishali Pharma Limited - Total Liabilities Trend (2013–2025)
This chart illustrates how Vaishali Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vaishali Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Vaishali Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Imugene Limited
PINK:IUGNF
|
USA | $38.56 Million |
|
Terrain Minerals Ltd
AU:TMX
|
Australia | AU$566.54K |
|
Castle Peak Holdings Public Company Limited
BK:CPH
|
Thailand | ฿568.02 Million |
|
Plaza Centers NV
WAR:PLZ
|
Poland | zł162.91 Million |
|
TVA Group Inc
PINK:TVAGF
|
USA | $220.69 Million |
|
Scandinavian Real Heart AB (Publ)
F:7820
|
Germany | €13.59 Million |
|
Salarius Pharmaceuticals Inc
NASDAQ:SLRX
|
USA | $1.85 Million |
|
Genesis Fertility Center Public Company Limited
BK:GFC
|
Thailand | ฿90.39 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Vaishali Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.02 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vaishali Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vaishali Pharma Limited (2013–2025)
The table below shows the annual total liabilities of Vaishali Pharma Limited from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹449.29 Million | +21.05% |
| 2024-03-31 | ₹371.16 Million | -3.28% |
| 2023-03-31 | ₹383.76 Million | -30.57% |
| 2022-03-31 | ₹552.70 Million | -13.24% |
| 2021-03-31 | ₹637.05 Million | +42.13% |
| 2020-03-31 | ₹448.23 Million | -5.34% |
| 2019-03-31 | ₹473.52 Million | +8.30% |
| 2018-03-31 | ₹437.22 Million | +7.21% |
| 2017-03-31 | ₹407.80 Million | -12.34% |
| 2016-03-31 | ₹465.19 Million | +9.30% |
| 2015-03-31 | ₹425.60 Million | -15.48% |
| 2014-03-31 | ₹503.56 Million | +9.93% |
| 2013-03-31 | ₹458.09 Million | -- |